Table 2.
Performance metrics comparing mpMRI and micro-ultrasound
| A. For detection of GG ≥2 PCa (39% of cases) | |||||
|---|---|---|---|---|---|
|
| |||||
| Modality | Sensitivity | Specificity | PPV | NPV | |
| mpMRI | 90% (371/411) | 22% (136/629) | 43% (371/864) | 77% (136/176) | |
| Micro-ultrasound | 94% (386/411) | 22% (138/629) | 44% (386/877) | 85% (138/163) | |
| p (non-inferiority) | <0.001 | <0.001 | <0.001 | <0.001 | |
| p (superior) | 0.03 | 0.45 | 0.32 | 0.04 | |
|
| |||||
| B. For GG ≥3 (19% of cases) | |||||
|
| |||||
| Modality | Sensitivity | Specificity | PPV | NPV | |
|
| |||||
| mpMRI | 94% (145/154) | 17% (112/642) | 21% (145/675) | 93% (112/121) | |
| Micro-ultrasound | 93% (144/154) | 21% (136/642) | 22% (144/657) | 93% (136/146) | |
| p (non-inferiority) | <0.001 | <0.001 | <0.001 | <0.001 | |
| p (superior) | 0.59 | 0.06 | 0.43 | 0.41 | |
|
| |||||
| C. PPV by PI-RADS and PRI-MUS score | |||||
|
| |||||
| 3 | 4 | 5 | Unknown | 4 or 5 | |
|
| |||||
| MRI PI-RADS | 14% | 38% | 62% | 49% | 40% |
| US PRI-MUS | 19% | 39% | 61% | 46% | 42% |
GG: Gleason grade; mpMRI: multiparametric magnetic resonance imaging; NPV: negative predictive value; PCa: prostate cancer; PI-RADS: Prostate Imaging-Reporting and Data System; PRI-MUS: Prostate Risk Identification using Micro-ultrasound; PPV: positive predictive value; US: ultrasound.